Can a ‘flawless’ live vector vaccine strain be engineered?

This publication has 50 references indexed in Scilit:

• Influence of Vector-Encoded Cytokines on Anti-SalmonellaImmunity: Divergent Effects of Interleukin-2 and Tumor Necrosis Factor Alpha
  Infection and Immunity, 2001
• Phase 2 Clinical Trial of AttenuatedSalmonella entericaSerovar Typhi Oral Live Vector Vaccine CVD 908-htrAin U.S. Volunteers
  Infection and Immunity, 2000
• Bacterial fitness and plasmid loss: the importance of culture conditions and plasmid size
  Canadian Journal of Microbiology, 1998
• Display of β-lactamase on the Escherichia coli surface: outer membrane phenotypes conferred by Lpp′–OmpA′–β-lactamase fusions
  Protein Engineering, Design and Selection, 1996
• Metabolic load and heterologous gene expression
  Biotechnology Advances, 1995
• Evaluation of the hok/sok killer locus for enhanced plasmid stability
  Biotechnology & Bioengineering, 1994
• Salmonella typhi Vaccine Strain CVD 908 Expressing the Circumsporozoite Protein of Plasmodium falciparum: Strain Construction and Safety and Immunogenicity in Humans
  The Journal of Infectious Diseases, 1994
• Use of the nirB Promoter to Direct the Stable Expression of Heterologous Antigens in Salmonella Oral Vaccine Strains: Development of a Single–Dose Oral Tetanus Vaccine
  Nature Biotechnology, 1992
• High-level expression of recombinant genes in Escherichia coli is dependent on the availability of the dnaY gene product
  Gene, 1989
• Live oral Salmonella vaccines: potential use of attenuated strains as carriers of heterologous antigens to the immune system
  Parasite Immunology, 1987